Zipeprol

R05DB15(WHO) BR:Class F2(Prohibited psychotropics)CA:Schedule IIIDE:Anlage II(Authorized trade only, not prescriptible)UK:Class BUS:Schedule IUN:Psychotropic Schedule II 1-methoxy- 3-[4-(2-methoxy- 2-phenylethyl)piperazin- 1-yl]- 1-phenylpropan- 2-ol 34758-83-3N 36910 33868Y G5MUV8139H D07390Y DTXSID00865732 Interactive image OC(CN1CCN(CC1)CC(OC)c2ccccc2)C(OC)c3ccccc3 InChI=1S/C23H32‍‍‍‍‍‍​​​‍​​​​​​N2O3/c1-27-22(19-9-5-3-6-10-19)18-25-15-13-24(14-16-25)17-21(26)23(28-2)20-11-7-4-8-12-20/h3-12,21-23,26H,13-18H2,1-2H3YKey:VSTNNAYSCJQCQI-UHFFFAOYSA-NY Zipeprolis a centrally actingcough suppressantdeveloped in France in the 1970s.It is not amorphinanderivative (in contrast to bothcodeineanddextromethorphan). Zipeprol acts as a local anaesthetic and hasmucolytic,antihistamineandanticholinergicproperties.It is sold with several brand names such asZinoltaandRespilene. It is not available in the United States or Canada and has been discontinued in Europe. It is still available in some countries in Asia and South America. Zipeprol has been misused in Korea as adeliriant. Such use is quite dangerous due to the risk of seizures and neurological damage at high dosages.